CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
OPERATING EXPENSES
General and administrative	$ 225	$ 472
Research and development	157	350
Total operating expenses	382	822
Interest and other expenses, net	11	56
Loss from continuing operations before taxes	393	878
Income tax benefit	(14)	(162)
NET LOSS	379	716
Less: Net Loss attributable to the noncontrolling interest	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 379	$ 716
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.01	$ 0.02
Basic and diluted shares outstanding (in shares)	40,885	40,885